Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Обзор

This project is a prospective, multicenter, randomized controlled clinical study. The subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The classical Bu / Cy scheme or MCBC scheme was used for pretreatment. The primary endpoint of the study was the 3-year recurrence-free survival rate after allogeneic hematopoietic stem cell transplantation, and the secondary endpoints were 3-year overall survival rate, recurrence rate, treatment-related mortality, and pretreatment-related toxicity.

Вмешательства

• Препарат MCBC regimen
  using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
• Препарат Bu/Cy regimen
  control group, the standard conditioning regimen Busulfan/Cyclophosphamide

Первичные конечные точки

• Relapse Free Survival [Срок оценки: 3 year post-HSCT]

Вторичные конечные точки (5)

• Overall Survival [Срок оценки: 3 year post-HSCT]
• cumulative incidence relapse rate [Срок оценки: 3 year post-HSCT]
• Non-relapse mortality [Срок оценки: 3 year post-HSCT]
• toxicity of conditioning regimen [Срок оценки: 24w post-HSCT]
• Immune reconstitution post-HSCT [Срок оценки: 24w post-HSCT]

Критерии участия

Критерии включения

• Refractory / relapsed AML.
• Patients with a HLA matched related or unrelated donor (9\~10/10) or haplo-identical related donor, plan to receive HSCT.
• Age ≤ 60 years old, men and women are not limited.
• The Eastern Oncology Collaborative Group Physical Status Assessment ( ECOG-PS ) was 0-2 points.
• Informed consent must be signed before the start of the study procedure. Informed consent must be signed by the patient or his or her immediate family members who are 18 years of age or older ; informed consent was signed by the legal guardian for children and adolescent patients under 18 years old. Considering the patient 's condition, if the patient 's signature is not conducive to the treatment of the disease, the informed consent is signed by the legal guardian or the patient 's immediate family.

Критерии исключения

• Have a history of cancer and have received any treatment for this tumor in the past 3 years. But remove superficial bladder cancer, skin basal cells or squamous cell carcinoma, cervical epithelium. Intraepithelial neoplasia ( CIN ) or prostatic intraepithelial neoplasia ( PIN ).
• MPAL.
• It is known that the serological reaction of HIV or active hepatitis C virus is positive.
• The inability to cooperate with the requirements of research, treatment and monitoring due to mental illness or other conditions.
• Pregnant patients or patients who could not take appropriate contraceptive measures during treatment.
• Previously received hematopoietic stem cell transplantation.
• Active heart disease, defined as one or more of the following :

• ) Uncontrolled or symptomatic angina history.
• ) Myocardial infarction less than 6 months away from the study.
• ) Have a history of arrhythmia requiring drug treatment or severe clinical symptoms.
• ) Uncontrolled or symptomatic congestive heart failure ( > NYHA class 2 ).
• ) The ejection fraction is lower than the lower limit of the normal range.
• Researchers evaluated that is not suitable for the group.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06133556 · IIT2023023-EC-2

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗